Targeting ecDNA for Aggressive Cancer Treatment

Targeting ecDNA for Aggressive Cancer Treatment

theguardian.com

Targeting ecDNA for Aggressive Cancer Treatment

A new study reveals that targeting ecDNA, small loops of rogue genetic material found in many aggressive cancers, could lead to new treatments for hard-to-treat cancers.

English
United Kingdom
HealthCancerResearchTreatmentMedicineGenetics
Stanford UniversityCancer Research UkUs National Cancer InstituteFrancis Crick InstituteBoundless Bio
Paul MischelDavid ScottCharles Swanton
What is the main discovery of this study?
Extrachromosomal DNA (ecDNA), small loops of rogue genetic material, are found in many aggressive cancers, contributing to their resistance to chemotherapy.
Who funded this research and what is its significance?
The research, funded by Cancer Grand Challenges, suggests a new path towards treating aggressive cancers by targeting ecDNA, potentially improving treatment outcomes and patient prognosis.
How many patients and tumor types were included in the study?
The study analyzed nearly 15,000 UK patients across 39 tumor types, revealing that over 17% contained ecDNA, particularly in breast, brain, and lung cancers.
What is a potential new treatment strategy mentioned in the study?
CHK1 inhibitors, currently in early clinical trials, show promise in selectively destroying ecDNA-containing tumor cells, potentially offering new treatment strategies for aggressive cancers.
How does ecDNA contribute to cancer growth and treatment resistance?
ecDNA carries cancer-driving genes and immune-suppressing genes, promoting tumor growth and evasion of the body's defenses, and its uneven replication boosts the tumor's resilience to drugs.